Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

IL-1[beta] binding antibodies for use in treating cancer

A technology that combines antibodies and cancer, applied in the direction of antibodies, antibody medical components, lung cancer vaccines, etc., can solve the problems of limited survival and incurable diseases of patients

Pending Publication Date: 2020-02-21
NOVARTIS AG
View PDF92 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Likewise, while current standard of care has provided significant improvement in outcome for other cancers with at least some inflammatory basis, for patients who progress on chemotherapy, the vast majority have incurable disease with limited survival

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • IL-1[beta] binding antibodies for use in treating cancer
  • IL-1[beta] binding antibodies for use in treating cancer
  • IL-1[beta] binding antibodies for use in treating cancer

Examples

Experimental program
Comparison scheme
Effect test

example

[0476] The following examples are provided to aid in the understanding of the invention but are not intended and should not be construed as limiting its scope in any way.

example 1

[0478] A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating canaginumab compared with placebo as adjuvant therapy in stage II-IIIA and IIIB (T>5cm N2) completely resected ( Efficacy and Safety in Adult Subjects with Small Cell Lung Cancer (NSCLC) in R0)

[0479] The purpose of this prospective, multicenter, randomized, double-blind, placebo-controlled, phase III study was to evaluate the efficacy of AJCC / UICC v.8 II-IIIA and IIIB (T>5cm N2 Efficacy and safety of canaginumab as adjuvant therapy following standard of care in NSCLC subjects.

[0480] Research design

[0481]This Phase III study CACZ885T2301 will enroll adult subjects with completely resected (R0) NSCLC AJCC / UICC v.8 II-IIIA and IIIB (T>5cm and N2) disease. Subjects will have completed standard-of-care adjuvant therapy for their NSCLC, including cisplatin-based chemotherapy and mediastinal radiotherapy, if applicable, prior to screening or randomization to this study. If possi...

example 2A

[0519] Blocking IL-1β signaling alters blood vessels in the skeletal microenvironment

[0520] Background: We have recently identified interleukin-1β (IL-1β) as a potential biomarker to predict increased risk of developing bone metastases in breast cancer patients. Furthermore, we have shown that blocking IL-1β activity inhibits bone metastasis of breast cancer cells that have spread in bone and reduces tumor angiogenesis. We hypothesized that the interaction between IL-1β and IL-1R also promotes neovascularization in the bone microenvironment that stimulates metastatic development at this site.

[0521] Objective: To study the effect of blocking IL-1β activity on angiogenesis in bone.

[0522] METHODS: In mice treated with 1 mg / kg of IL-1R antagonist (anakinra) for 21 / 31 days and IL-1β antibody canaginumab (Ilaris) for 0-96 hours or The effects of IL-1R inhibition on trabecular bone vessels were determined in genetically engineered IL-1R1 knockout (KO) mice. Blood vessels ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Use of an IL-1[beta] binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for thetreatment and / or prevention of cancer with at least partial inflammatory basis.

Description

technical field [0001] The present invention relates to the use of IL-1β binding antibodies or functional fragments thereof for the treatment and / or prevention of cancers having an at least part inflammatory basis, eg cancers as described herein, eg lung cancer. Background technique [0002] Lung cancer is one of the most common cancers in men and women worldwide. Lung cancer is divided into two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The types are distinguished on the basis of histological and cytological observations, with NSCLC accounting for approximately 85% of lung cancer cases. Non-small cell lung cancer is further divided into subtypes including, but not limited to, squamous cell carcinoma, adenocarcinoma, bronchoalveolar carcinoma, and large cell (undifferentiated) carcinoma. Despite a variety of treatment options, the 5-year survival rate is only between 10% and 17%. Therefore, there is still a need to develop new treatment o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24A61K39/00
CPCA61K2039/505A61K2039/54A61K2039/545A61K2039/828A61K2039/836A61K2039/82A61K2039/868A61K39/00114A61K2039/86C07K16/245A61P35/00A61K31/282C07K16/2896G01N33/57423A61K9/0019A61K2300/00
Inventor M·利格罗斯-萨伊兰P·马特查巴T·索伦P·里德凯尔P·莉比P·奥特韦尔Y·Y·劳M·杜根
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com